Status:
UNKNOWN
Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Squamous Cell Carcinoma of the Oral Cavity
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Oral squamous cell carcinoma (OSCC) has the highest annual increase in the rate of death among the top 10 leading cancers in Taiwan. This research aimed to explore whether increased anti-tumor immunit...
Detailed Description
Oral squamous cell carcinoma (OSCC) has the highest annual increase in the rate of death among the top 10 leading cancers in Taiwan. This research aimed to explore whether increased anti-tumor immunit...
Eligibility Criteria
Inclusion
- Oral squamous cell carcinoma (OSCC) subjects without other cancer diagnosis
- healthy donors (HDs)
Exclusion
- pregnant woman
Key Trial Info
Start Date :
March 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 21 2021
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04387682
Start Date
March 22 2017
End Date
March 21 2021
Last Update
May 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100